Gabren

Gabren - General Information

Gabren is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. Gabren has been investigated for many diseases besides epilepsy, including Parkinson's disease, schizophrenia, clinical depression and anxiety disorder with varying success.

Pharmacology of Gabren

Gabren, a fatty acid derivative, is a GABA receptor agonist used to treat the symptoms of epilepsy.

Additional information about Gabren

Gabren Indication: Indicated for the treatment of epilepsy.
Mechanism Of Action: Gabren binds to both GABA_A and GABA_B receptors located on the terminals of primary afferent fibers. Binding to GABA_A results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABA_B receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Progabide
Synonyms: Progabidum [Inn-Latin]; Progabide [Usan-Ban-Inn]; Progabida [Inn-Spanish]; Halogabide
Drug Category: Antiparkinson Agents; Antidyskinetics; Antidepressants; Anticonvulsants
Drug Type: Small Molecule; Approved

Other Brand Names containing Progabide: Gabren; Gabrene;
Absorption: Well absorbed with a bioavailability of 60%
Toxicity (Overdose): Not Available
Protein Binding: 95%
Biotransformation: Hepatic
Half Life: 4 hours
Dosage Forms of Gabren: Not Available
Chemical IUPAC Name: 4-[[(E)-(4-chlorophenyl)-(3-fluoro-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]amino]butanamide
Chemical Formula: C17H16ClFN2O2
Progabide on Wikipedia: https://en.wikipedia.org/wiki/Progabide
Organisms Affected: Humans and other mammals